TransCode Therapeutics says Australia accepts patent application for siRNA cancer nanoparticle delivery
Bitget2026/09/22 12:06- TransCode Therapeutics reported patent progress in Australia, citing acceptance of an application covering siRNA cancer therapies using nanoparticle delivery.
- Japan granted a patent covering RNA immunomodulatory compositions designed to activate innate immune pathways such as RIG-I in tumors.
- Australian application covers iron-oxide, dextran-coated nanoparticles with covalently linked siRNA, spanning broad oncology use.
- Japanese claims include approaches aimed at cancers expressing miR-21, including nanoparticle-enabled delivery systems.
- Australian patent, if granted, is expected to expire on Sept. 6, 2039.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Foreign capital accelerates withdrawal, Indian stock market faces "the worst consecutive decline in twenty-five years"!
Foreign investors are accelerating their sell-off of Indian stocks — with a net sale of approximately $1.06 billion on Wednesday alone, significantly higher than the previous five-day average of around $720 million. Year-to-date net sales have reached $27.8 billion, setting a new historical record. Meanwhile, if the Nifty 50 and Sensex close lower this week, it will mark the longest consecutive weekly decline in 25 years. The market closure on Friday has further heightened investor caution, and there will be some pressure for position adjustments when trading resumes next week.
Lunit cuts conversion price on convertible bond to KRW 18,264 from KRW 19,450
Cardano Hits $0.25 on Petrobras Adoption: Next ADA Buy Zone Revealed
Crypto prices
More
